Clinical trial · no report yet · Phase 2
NCT03410043
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
- NCT03410043 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Osimertinib; Radiation Therapy; Therapeutic Conventional Surgery
- Arms
- Group I (LCT) · Experimental
- Group II (no LCT) · Experimental
- Enrollment
- 173
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI), National Comprehensive Cancer Network
- Start
- Jan 17, 2018
- Primary completion
- Apr 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03410043 · updated Sep 18, 2026